Revolutionizing mRNA Analytics: Rapid Quantification for Multivalent Vaccine Development

The recent expansion of mRNA vaccine and therapeutic candidates under development in response to the COVID-19 pandemic has prompted significant interest in improving analytical methodologies for mRNA analysis.

This webinar showcases the VaxArray platform’s applications to mRNA analytics, with a focus on VaxArray’s applicability as an identity and mRNA content assay for multivalent mRNA vaccines using the newly released nuIQ product line. The platform enables the confirmation of identity and simultaneous quantification of all constructs in multivalent naked mRNA samples and lipid nanoparticle (LNP)-encapsulated mRNA samples in under two hours.

In addition to highlighting VaxArray’s various applications in mRNA analytics, a case study demonstrates a VaxArray assay capable of specific and simultaneous quantification of each of four influenza hemagglutinin (HA) mRNA constructs relevant to seasonal influenza vaccines.

The mRNA fluIQ assay was specifically designed for universal reactivity with HA mRNAs, regardless of source or codon optimization scheme, and provided a robust and efficient tool for streamlined mRNA quantification. In addition, they will highlight recent joint published work with Pfizer on a custom assay for identity and quantity in a multivalent mRNA vaccine candidate.

Attendees will learn about how the VaxArray platform streamlines the identification and measurement of multivalent naked or LNP-encapsulated mRNA in under two hours, enhancing efficiency compared to existing technologies. They will also gain insights a case study showcasing the platform’s capability to universally quantify multivalent influenza HA mRNA constructs.

Register for this webinar to explore how this innovative platform can support rapid and reliable mRNA analytics in diverse applications.

Speaker

Dr. Erica Dawson, Chief Research and Development Officer, InDevR

Dr. Erica Dawson has been integral in leading the research and development and transfer to manufacturing of InDevR products since 2006. Dr. Dawson manages InDevR’s cross-functional R&D and engineering departments, guiding and overseeing the development of the company’s extensive technology portfolio and related intellectual property.

Additionally, she collaborates with production, customer service and sales and marketing to promote the commercial success of these technologies. Dr. Dawson has acted as the Program Manager or Principal Investigator on most of InDevR’s government-funded contracts and grants, including the recently completed $14.7M contract with the Biomedical Advanced Research and Development Authority (BARDA) for FluChip-8G, for which Dr. Dawson successfully led the company in its first 510(k) clearance in April 2019. Dr. Dawson has 15 years’ experience in project/program management and medical device/life science tools development and life cycle management.

Dr. Dawson earned her PhD in Analytical Chemistry from The University of North Carolina at Chapel Hill, holds a BS (summa cum laude) from Hartwick College in Oneonta, NY, and completed her postdoctoral training at the University of Colorado at Boulder. Erica has published a wide number of high-impact scientific publications and is a named inventor on numerous issued or pending US and worldwide patents.

Message Presenter